Servier Pharmaceuticals US
Servier is a global pharmaceutical group dedicated to improving patients' lives through innovative therapeutics. It is a leader in oncology and is expanding its neurology business, with a focus on rare diseases and unmet patient needs. The company invests over 20% of its revenue in research and development, and has a strong pipeline in oncology, neuroscience, and immuno-inflammation. Servier is committed to open and collaborative innovation, partnering with academic institutions, biotech, and pharmaceutical companies worldwide. It aims to become a renowned and innovative player in oncology, with a significant presence in cardiometabolism and venous diseases.
Industries
Nr. of Employees
Very Large (1000+)
Servier Pharmaceuticals US
Products
Oral IDH1 inhibitor (approved for selected AML indications; under investigation in other IDH1‑mutant tumors)
An orally administered targeted inhibitor of mutant IDH1 used in approved indications for relapsed/refractory and certain newly diagnosed AML patients and evaluated in other IDH1‑mutant malignancies including cholangiocarcinoma and glioma.
Oral MAT2A inhibitor (clinical development for MTAP‑deleted tumors)
An orally administered MAT2A inhibitor developed for tumors with MTAP deletion and evaluated in single-agent dose-escalation and combination arms to determine safety, PK/PD and preliminary efficacy with biomarker-based target engagement readouts.
Commercial portfolio of prescription and generic medicines
A global portfolio spanning oncology and other therapeutic areas, distributed through regional channels and supported by commercial infrastructure.
Oral IDH1 inhibitor (approved for selected AML indications; under investigation in other IDH1‑mutant tumors)
An orally administered targeted inhibitor of mutant IDH1 used in approved indications for relapsed/refractory and certain newly diagnosed AML patients and evaluated in other IDH1‑mutant malignancies including cholangiocarcinoma and glioma.
Oral MAT2A inhibitor (clinical development for MTAP‑deleted tumors)
An orally administered MAT2A inhibitor developed for tumors with MTAP deletion and evaluated in single-agent dose-escalation and combination arms to determine safety, PK/PD and preliminary efficacy with biomarker-based target engagement readouts.
Commercial portfolio of prescription and generic medicines
A global portfolio spanning oncology and other therapeutic areas, distributed through regional channels and supported by commercial infrastructure.
Services
Patient access and support programs
Assistance services for therapy access, reimbursement navigation and financial assistance enrollment to support patients prescribed specialty therapies.
Company-sponsored clinical development and integrated biomarker services
End-to-end execution of internal clinical development programs including protocol design, global site management, integrated PK/PD and translational biomarker strategies and investigator collaborations.
Patient access and support programs
Assistance services for therapy access, reimbursement navigation and financial assistance enrollment to support patients prescribed specialty therapies.
Company-sponsored clinical development and integrated biomarker services
End-to-end execution of internal clinical development programs including protocol design, global site management, integrated PK/PD and translational biomarker strategies and investigator collaborations.
Expertise Areas
- Oncology clinical development (Phase 1–3) with global execution
- Combination regimen development in oncology
- Translational medicine and biomarker-driven development
- Discovery and preclinical validation of targeted small molecules
Key Technologies
- Next-generation sequencing (NGS)
- High-sensitivity digital PCR
- Flow cytometry for minimal residual disease
- Immunohistochemistry (IHC)